title: Interstitial nephritis in a patient taking sorafenib.
authors.forename: Hassane
authors.initials: H
authors.lastname: Izzedine
authors.forename: Isabelle
authors.initials: I
authors.lastname: Brocheriou
authors.forename: Olivier
authors.initials: O
authors.lastname: Rixe
authors.forename: Gilbert
authors.initials: G
authors.lastname: Deray
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology; D001557:Benzenesulfonates / Q000009:adverse effects* / Q000494:pharmacology; D001706:Biopsy; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D018572:Disease-Free Survival; D006801:Humans; D007249:Inflammation; D007668:Kidney / Q000473:pathology; D007680:Kidney Neoplasms / Q000188:drug therapy; D007962:Leukocytes / Q000378:metabolism; D008297:Male; D009395:Nephritis, Interstitial / Q000139:chemically induced*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000009:adverse effects* / Q000494:pharmacology; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib